Clinical and economic issues associated with switching between triptans in clinical practice

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 375-379

  Dowson, A J ^a   Fuat, A ^b   Gruffydd Jones, K ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Falchion Orthodontics   (United Kingdom)

^c Box ^*  (United Kingdom)

Author keywords

Clinical guidelines; Economic costs; Migraine; Switching; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG PREFERENCE; DRUG TOLERABILITY; DRUG USE; HEALTH CARE COST; HUMAN; MIGRAINE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; SIDE EFFECT;

DECISION MAKING; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; INDOLES; MIGRAINE DISORDERS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 16844373230     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X30716     Document Type: Review

References (17)

1. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
2. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: 2nd edn. Cephalalgia 2000;20:765-86
3. Dowson AJ, Lipscombe S, Sender J, et al. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002;18:414-39
4. Lipscombe S, Rees T, Dowson AJ. Tailoring migraine management in primary care to the needs of the individual patient. Headache Care 2004;1:147-57
5. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75
6. Belsey JD. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001;4:105-27
7. Loder E, Brandes JL, Silberstein S, et al. Preference comparison of rizatriptan ODT 10 mg and sumatriptan 50 mg tablet in migraine. Headache 2001;41:745-53
8. Pascual J, Munoz R, Leira R. An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. Cephalalgia 2001;21:680-4
9. Dowson AJ, Sender J, Lipscombe S, et al. Establishing principles of migraine management in primary care. Int J Clin Pract 2003;57:492-507
10. Lipton RB, Goadsby PJ, Sawyer JPC, et al. Migraine: diagnosis and assessment of disability. Rev Contemp Pharmacother 2000;11:63-73
11. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 2001;76:1093-101
12. Coukell AJ, Lamb HM. Sumatriptan: a pharmacoeconomic review of its use in migraine. Pharmacoeconomics 1997;11:473-90
13. Savani N, Martin A, Browning D. Switching patients with migraine from sumatriptan to other triptans increases primary care costs. Int J Clin Pract 2004;58:758-63
14. Williams D, Cahill T, Dowson A, et al. Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 2002;18:1-9
15. Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002;18:129-138
16. Bullock R, Connolly C. Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it? Int J Geriatr Psychiatry 2002;17:288-9
17. Stark S, Spierings EL, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513-20